Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluating the therapeutic effectiveness of omalizumab in patients with poor-controlled asthma

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: LI, Chang-Yi (Antai Medical Care Corporation Antai Tian-Sheng Memorial hospital Pharmacy Department)
  • Co-author(s): Chang-Yi LI: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Yu-Zi ZHENG: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Bo-Wei HUANG: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Hsiang-Yu CHEN: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Li-Chen CHAN: Department of Pharmacy, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
    Chi-Cheng LIN: Department of Thoracic, Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan, Province of China
  • Abstract:

    Background

    Asthma is an inflammatory disorder of respiratory tract, which has been defined as a chronic disease by WHO. Based on countless researches, several medical associations worldwide have published respective therapeutic instructions of asthma and kept updating annually, such as the well-known GINA guideline. As time goes by, numerous..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 21 September 2019

FIP Congresses